Sana Biotechnology, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
8. Property and equipment, net
Property and equipment, net consists of the following:
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| (in thousands) | ||
| Laboratory equipment | $41,905 | $38,462 |
| Leasehold improvements | 39,061 | 39,061 |
| Computer equipment, software, and other | 4,172 | 4,138 |
| Total property and equipment, at cost | 85,138 | 81,661 |
| Less: Accumulated depreciation | (62,026) | (54,755) |
| Property and equipment, net | $23,112 | $26,906 |
Depreciation expense was $3.0 million and $3.2 million for the three months ended September 30, 2026 and 2025, respectively, and $7.6 million and $9.7 million for the nine months ended September 30, 2026 and 2025, respectively. In the second quarter of 2025, the Company recognized non-cash impairment losses related to construction in progress, laboratory equipment, and leasehold improvements for the Company's manufacturing facility in Bothell, Washington (the Bothell facility) and a portion of the Company's laboratory and office space in Seattle, Washington (the Seattle facility). Refer to Note 11, Impairment of long-lived assets for further information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.